EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Treatment‐Free Remission in Chronic Phase Chronic Myeloid Leukemia After Nilotinib De‐Escalation: 96‐Week Update of the DANTE Study

Alessandra Iurlo iD, Massimo Breccia iD, Fabio Stagno iD, Elisabetta Abruzzese iD, Fabrizio Pane iD, Immacolata Attolico iD, Paolo Sportoletti iD, Marco Cerrano iD, Sara Galimberti iD, Barbara Scappini iD, Maurizio Miglino iD, Sergio Siragusa iD und 7 weitere

Hematological Oncology · 2025-09 · 43 (5)

DOI: 10.1002/hon.70126 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Hematological Oncology, online erschienen am 08.08.2025. Verfasst von Alessandra Iurlo und 18 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy. Hauptthemen laut MEDLINE: Pyrimidines, Leukemia, Myeloid, Chronic-Phase, Protein Kinase Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novartis.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Treatment‐free remission (TFR) in chronic myeloid leukemia (CML) can be considered for patients in sustained deep molecular response (DMR) who can discontinue tyrosine kinase inhibitors (TKIs) while maintaining responses. Studies suggest that TKI de‐escalation before TFR is feasible. This phase II study evaluated nilotinib de‐escalation outcomes in adults with CML in chronic phase (CP) treated with first‐line nilotinib for ≥ 3 years and in sustained DMR for ≥ 1 year. The study had four phases: screening, de‐escalation (week 0–48), TFR (week 48–144) and follow‐up. During de‐escalation, patients received nilotinib 300 mg once daily, and those with sustained DMR entered TFR and discontinued nilotinib. Patients with major molecular response (MMR) but without sustained DMR continued nilotinib. At the data cut‐off, 107 patients entered, and 98 (91.6%) completed de‐escalation. TFR was entered by 90 patients (84.1%) with sustained DMR. At 96 weeks, 71/107 patients (66.4%) were in full TFR; 64/90 patients (71.1%) who entered TFR remained in ≥ MMR, and the median time‐to‐loss of MMR was not reached. During TFR, adverse events occurred in 64 patients (71.1%), including one serious event (pneumonia). Our data suggest that the de‐escalation of nilotinib before a TFR attempt in CML‐CP patients with sustained DMR can be a successful dose optimization strategy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyrimidinesLeukemia, Myeloid, Chronic-PhaseProtein Kinase InhibitorsHumansMaleFemaleMiddle AgedAdultAgedRemission InductionYoung AdultFollow-Up StudiesAged, 80 and over

Stichwörter der Autor:innen

chronic myeloid leukemianilotinibsustained deep molecular responsetreatment‐free remission

Substanzen

nilotinibPyrimidinesProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • Hematology, Department of Translational and Precision Medicine, Policlinico Umberto I, Sapienza University, Rome, Italy.
  • Hematology Unit, AOU Policlinico "G. Martino", University of Messina, Messina, Italy.
  • Hematology, S. Eugenio Hospital, Tor Vergata University, ASL Roma 2, Rome, Italy.
  • Department of Clinical Medicine and Surgery, Federico II University of Naples, Naples, Italy.
  • Department of Emergency and Organ Transplantation (D.E.T.O.), University of Bari, Hematology Section, Bari, Italy.

ORCID-Profile: Alessandra Iurlo, Massimo Breccia, Fabio Stagno, Elisabetta Abruzzese, Fabrizio Pane, Immacolata Attolico, Paolo Sportoletti, Marco Cerrano, Sara Galimberti, Barbara Scappini, Maurizio Miglino, Sergio Siragusa, Isabella Capodanno, Aurelio Pio Nardozza, Giuseppe Saglio, Gianantonio Rosti

Förderung

  • Novartis

Zitieren

APA

Iurlo, A., Breccia, M., Stagno, F., Abruzzese, E., Pane, F., Attolico, I., Sportoletti, P., Cerrano, M., Galimberti, S., Scappini, B., Miglino, M., Siragusa, S., Capodanno, I., Valsecchi, D., Nardozza, A. P., Misto, A., Coco, P., Saglio, G., & Rosti, G. (2025). Treatment‐Free Remission in Chronic Phase Chronic Myeloid Leukemia After Nilotinib De‐Escalation: 96‐Week Update of the DANTE Study. Hematological Oncology, 43(5). https://doi.org/10.1002/hon.70126

Vancouver

Iurlo A, Breccia M, Stagno F, Abruzzese E, Pane F, Attolico I, et al. Treatment‐Free Remission in Chronic Phase Chronic Myeloid Leukemia After Nilotinib De‐Escalation: 96‐Week Update of the DANTE Study. Hematological Oncology. 2025;43(5). doi:10.1002/hon.70126

BibTeX
@article{Iurlo2025,
  author = {Iurlo, Alessandra and Breccia, Massimo and Stagno, Fabio and Abruzzese, Elisabetta and Pane, Fabrizio and Attolico, Immacolata and Sportoletti, Paolo and Cerrano, Marco and Galimberti, Sara and Scappini, Barbara and Miglino, Maurizio and Siragusa, Sergio and Capodanno, Isabella and Valsecchi, Diletta and Nardozza, Aurelio Pio and Misto, Alessandra and Coco, Paola and Saglio, Giuseppe and Rosti, Gianantonio},
  title = {Treatment‐Free Remission in Chronic Phase Chronic Myeloid Leukemia After Nilotinib De‐Escalation: 96‐Week Update of the DANTE Study},
  journal = {Hematological Oncology},
  year = {2025},
  volume = {43},
  number = {5},
  doi = {10.1002/hon.70126}
}
Kostenlos starten →